CMC Module 3, drafted from the batch record up.
CMC Module 3 support is in active development for Q3 2026. The workflow below describes the shipping target. Asthra will consolidate BMRs, CoAs, specifications, validation reports, and stability data into structured CTD Module 3 narratives — drug substance and drug product — with every spec value, method, and justification cited to the source.
Manufacturing-floor evidence, indexed.
Batch manufacturing records
Process steps, parameters, in-process controls. Asthra extracts the procedural narrative for §3.2.S.2 and §3.2.P.3.
Certificates of analysis
Release results across batches. Asthra reconciles spec values against acceptance criteria with cell-level citations.
Method validation reports
HPLC, GC, dissolution, microbiological methods. Feed §3.2.S.4.3 and §3.2.P.5.3 with method summaries.
Stability data
Long-term, accelerated, and intermediate-condition data. Asthra constructs stability tables with statistical context preserved.
Specifications
Drug-substance and drug-product spec docs with justification trail. Mapped section-by-section into §3.2.S.4.1 / §3.2.P.5.1.
Prior submissions
For continuity with previously approved markets — keeps Module 3 narratives consistent across regulatory filings.
From batch to filing.
Load the quality dossier
BMRs, CoAs, methods, specs, stability — Asthra ingests, classifies by CTD section, and surfaces any missing documents before drafting.
Approve the section map
Asthra proposes which document supports each Module 3 subsection. CMC SMEs swap in newer batches, exclude legacy data, and confirm the source set.
Draft Module 3 narratives
§3.2.S.1 through §3.2.P.8 drafted to ICH M4Q. Asthra constructs spec-comparison tables, manufacturing-step descriptions, and stability-data summaries with cell-level citations.
SME review & reconciliation
Quality, manufacturing, and analytical reviewers refine sections in Word — chat with Asthra to swap a method, integrate a new batch, or align with a prior submission.
Hand off to publishing
Final Module 3 sections ship to the publishing team in eCTD-ready form, with the audit ledger embedded — ready for FDA, EMA, or PMDA filing.
What changes for the CMC writing team.
Manual Module 3 drafting
- −12–20 weeks for full Module 3 first draft
- −Spec-table assembly across batches: weeks of analyst time
- −Method narratives rewritten for every filing region
- −Stability data reconciled by hand against shelf-life claims
- −Cross-section consistency depends on writer memory
Module 3 drafting with Asthra
- +First draft in weeks; review parallelizes across SMEs
- +Spec tables auto-generated from CoAs with cell-level provenance
- +Method narratives reuse validated content across regions
- +Stability claims tied to the underlying data points
- +Citation graph keeps cross-section data consistent automatically
From the blog
- One Batch, a Dozen Tables: The Consistency Problem in CMC Module 3
A CMC / Module 3 dossier is mostly interlocking tables, and the same batch, impurity, and limit turn up across many of them. Keeping those appearances consistent, and traceable, is what makes Module 3 hard to automate — not the writing. Here's how we think about it.
- Operation TrialBlazer and Phase-Appropriate Requirements: What FDA's Modernization Push Asks of the Writing Organisation
FDA's Operation TrialBlazer aims to accelerate drug development from the pre-IND / IND transition through late-stage trials, with a Phase 1 IND Navigator, updated Phase 1 CMC resources, dose-selection guidance, master-protocol updates, and an explicit focus on phase-appropriate requirements. For regulatory writing teams, the implication is direct: every section now has to be scoped to the phase deliberately, with clear deferral language and reviewer-visible rationale.
- Parabilis's $670M IPO: What Parallel-Indication Writing Looks Like at Capital Scale
Parabilis Medicines raised $670M in a record-setting biotech IPO, giving it capital to advance zolucatetide toward Phase 3 in desmoid tumors while moving more aggressively into additional indications. For the writing organisation, that changes the operating model: shared molecule content, synchronised safety language, product-level CMC, and indication-specific clinical narratives now have to move in parallel.
- Lilly Buys 4E: Why Bolt-On Integration Is Becoming a Writing-Organisation Function
Eli Lilly's acquisition of 4E Therapeutics adds another non-opioid pain platform to its 2026 deal run. Against a broader biopharma backdrop of larger partnerships and rising China-sourced licensing, the durable problem is not deal execution — it is dossier integration: inherited IBs, agency history, CMC source documents, safety language, and clinical narratives have to be absorbed without creating long-term fragmentation.
Pilot Asthra
on a real Module 3.
30-day pilot. One product, one region. We benchmark Asthra's draft against your existing process — batch record to eCTD.